Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | CAR-T updates at COSTEM 2021

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of key highlights in the field of chimeric antigen receptor T-cell (CAR-T) therapy being discussed at the 2021 COSTEM meeting. Prof. Nagler discusses the approval of four CAR-T products for various forms of non-Hodgkin lymphoma, and the approval of one CAR-T product for multiple myeloma with another one pending. Prof. Nagler also describes how CAR-T may replace allogeneic transplantation and autologous transplantation and comments on the role of other immunotherapies. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.